Fluorinov Pharma Overview
- Founded
- 2008
- Status
- Acquired/Merged
- Latest Deal Type
- M&A
- Latest Deal Amount
- $31.7M
Fluorinov Pharma General Information
Description
Operator of a pharmaceutical company intended to develop fluorine-based novel, safer and more effective medicine. The company's services include developing small molecule product portfolio for Multiple Myeloma, Waldenström's Macroglobulinemia, Leukemia, Glioblastoma, Lung and Pancreatic Cancers and Central Nervous System disorders, enabling patients to avail therapeutics to treat and avoid cancer diseases.
Contact Information
Website
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Acquirer
Primary Office
- 101 College Street, MaRS Centre, South Tower
- Suite 300, L-349
- Toronto, Ontario M5G 1L7
- Canada
Fluorinov Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 27-Jan-2016 | $31.7M | 00.000 | 000.00 | Completed | Generating Revenue |
| 3. Early Stage VC | 07-Jan-2015 | 00.000 | Completed | Generating Revenue | ||
| 2. Early Stage VC | 07-Jun-2012 | $1.47M | $1.47M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 01-Jan-2010 | Completed | Generating Revenue |
Fluorinov Pharma Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| FACIT | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Ontario Institute for Cancer Research | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 | |
| StandUp Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |